PAVmed (PAVM) Financials

PAVmed logo
$1.14 -0.07 (-5.42%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$1.17 +0.04 (+3.35%)
As of 11/20/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for PAVmed

Annual Income Statements for PAVmed

This table shows PAVmed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-1.78 -5.65 -10 -19 -17 -35 -51 -89 -66 32 -3.77
Consolidated Net Income / (Loss)
-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Net Income / (Loss) Continuing Operations
-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Total Pre-Tax Income
-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Total Operating Income
-1.78 -5.65 -8.03 -11 -14 -23 -54 -91 -69 -44 -22
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 -0.09 -3.24 -3.97 -1.85 -0.15
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.38 2.45 3.00 0.07
Operating Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.38 2.45 3.00 0.07
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.59 3.61 6.42 4.84 0.22
Operating Cost of Revenue
- - - - - 0.00 0.59 3.61 6.42 4.84 0.22
Total Operating Expenses
1.78 5.65 8.03 11 14 23 54 88 65 43 22
Selling, General & Admin Expense
1.29 3.93 5.41 6.31 7.67 9.60 25 41 31 25 16
Marketing Expense
- - - - - 2.79 8.90 19 18 12 0.92
Research & Development Expense
0.49 1.72 2.62 4.25 6.63 11 20 25 14 5.93 4.49
Amortization Expense
- - - - - - 0.15 1.78 2.02 0.56 0.00
Total Other Income / (Expense), net
0.00 0.00 -1.49 -7.61 -2.97 -13 -1.73 -12 -10 73 19
Interest Expense
- 0.00 0.72 4.42 1.86 6.55 3.42 6.72 4.37 4.58 0.08
Interest & Investment Income
- - - - - - - 0.17 0.51 73 0.03
Other Income / (Expense), net
- 0.00 -0.76 -3.19 -1.11 -5.99 1.68 -5.61 -6.60 4.95 19
Income Tax Expense
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared
- 0.00 0.88 0.78 0.27 0.29 0.28 0.28 2.10 7.83 4.18
Net Income / (Loss) Attributable to Noncontrolling Interest
- - 0.00 -0.20 -0.81 -1.61 -5.78 -14 -15 -11 -2.87
Basic Earnings per Share
($0.16) ($0.44) ($0.71) ($0.81) ($0.54) ($1.45) ($0.65) ($15.03) ($9.16) $99.15 ($5.63)
Weighted Average Basic Shares Outstanding
11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 5.94M 7.23M 322.41K 670.47K
Diluted Earnings per Share
($0.16) ($0.44) ($0.71) ($0.81) ($0.54) ($1.45) ($0.65) ($15.03) ($9.16) $14.90 ($5.63)
Weighted Average Diluted Shares Outstanding
11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 5.94M 7.23M 2.17M 670.47K
Weighted Average Basic & Diluted Shares Outstanding
11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 98.42M 9.17M 16.79M 6.38M

Quarterly Income Statements for PAVmed

This table shows PAVmed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-23 -11 64 1.35 18 -13 -6.33 -1.83 -6.99 -5.48 -12
Consolidated Net Income / (Loss)
-19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60 -13
Net Income / (Loss) Continuing Operations
-19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60 -13
Total Pre-Tax Income
-19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60 -13
Total Operating Income
-14 -14 -12 -5.19 -5.45 -4.72 -4.84 -6.80 -8.04 -7.02 -6.73
Total Gross Profit
-0.73 -0.69 -0.39 -0.04 -0.03 -0.04 -0.05 -0.03 -0.08 -0.09 -0.12
Total Revenue
1.01 0.98 1.00 0.01 0.01 0.01 0.01 0.05 0.02 0.03 0.04
Operating Revenue
1.01 0.98 1.00 0.01 0.01 0.01 0.01 0.05 0.02 0.03 0.04
Total Cost of Revenue
1.74 1.67 1.38 0.05 0.04 0.04 0.06 0.09 0.10 0.12 0.16
Operating Cost of Revenue
1.74 1.67 1.38 0.05 0.04 0.04 0.06 0.09 0.10 0.12 0.16
Total Operating Expenses
13 13 11 5.15 5.42 4.68 4.79 6.77 7.96 6.93 6.61
Selling, General & Admin Expense
6.68 7.01 6.65 4.19 4.38 3.67 3.51 4.69 6.36 4.65 4.48
Marketing Expense
4.31 4.24 2.92 0.15 0.25 0.22 0.20 0.25 0.22 0.22 0.21
Research & Development Expense
1.94 1.64 1.54 0.81 0.79 0.79 1.09 1.83 1.39 2.07 1.92
Total Other Income / (Expense), net
-4.48 -1.23 72 6.33 24 -7.61 -1.17 4.04 6.97 0.42 -6.31
Interest Expense
2.39 0.77 1.42 0.01 0.06 0.00 0.01 0.01 3.43 0.00 0.01
Interest & Investment Income
0.07 0.11 72 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.01
Other Income / (Expense), net
-2.16 -0.57 1.35 6.34 24 -7.61 -1.17 4.05 10 0.42 -6.31
Income Tax Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Preferred Stock Dividends Declared
7.58 0.08 0.08 0.09 1.27 1.39 0.95 0.57 6.93 0.10 0.10
Net Income / (Loss) Attributable to Noncontrolling Interest
-3.30 -4.09 -3.69 -0.29 -0.35 -0.40 -0.63 -1.49 -1.00 -1.21 -1.38
Basic Earnings per Share
($2.62) ($1.19) $6.43 $4.17 $38.26 ($22.08) ($8.81) ($2.73) ($4.42) ($0.87) ($1.77)
Weighted Average Basic Shares Outstanding
8.69M 9.15M 10.01M 322.41K 462.54K 602.82K 718.49K 670.47K 1.58M 6.27M 6.64M
Weighted Average Diluted Shares Outstanding
8.69M 9.15M 44.48M 2.17M 1.75M 602.82K 29.67M 670.47K 1.58M 6.27M 8.00M
Weighted Average Basic & Diluted Shares Outstanding
9.43M 10.41M 11.07M 16.79M 17.62M 21.93M 29.67M 6.38M 7.27M 8.00M 8.00M

Annual Cash Flow Statements for PAVmed

This table details how cash moves in and out of PAVmed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.07 -0.18 0.95 6.69 -2.00 11 60 -38 -20 -18 0.35
Net Cash From Operating Activities
-1.25 -4.45 -6.61 -8.79 -13 -22 -41 -71 -52 -34 -5.21
Net Cash From Continuing Operating Activities
-1.25 -4.45 -6.61 -8.79 -13 -22 -41 -71 -52 -34 -5.21
Net Income / (Loss) Continuing Operations
-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Consolidated Net Income / (Loss)
-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Depreciation Expense
0.00 0.00 0.01 0.01 0.01 0.02 0.23 2.46 2.93 1.20 0.11
Non-Cash Adjustments To Reconcile Net Income
0.13 0.75 2.64 6.49 3.32 14 17 31 23 -64 -2.94
Changes in Operating Assets and Liabilities, net
0.39 0.44 -0.08 1.28 0.58 0.08 -1.57 -0.72 1.59 0.51 0.10
Net Cash From Investing Activities
0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -3.72 -4.74 0.76 -16 -0.03
Net Cash From Continuing Investing Activities
0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -3.72 -4.74 0.76 -16 -0.03
Purchase of Property, Plant & Equipment
0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -1.47 -1.54 -0.24 -0.06 -0.03
Acquisitions
- - - - - 0.00 -2.25 -3.20 - -16 0.00
Divestitures
- - - - - - - - - 0.35 0.00
Net Cash From Financing Activities
1.18 4.30 7.56 16 11 33 104 38 31 31 5.59
Net Cash From Continuing Financing Activities
1.18 4.30 7.56 16 11 33 104 38 31 31 5.59
Repayment of Debt
- - 0.00 -5.00 -0.37 -0.60 -15 0.00 -0.08 -0.53 0.00
Repurchase of Common Equity
-0.07 0.00 -0.39 0.00 - - -1.31 - - 0.00 -0.11
Issuance of Preferred Equity
- 0.00 3.04 - - - - 0.00 19 30 0.00
Issuance of Common Equity
0.00 5.30 0.07 14 5.48 16 117 0.44 1.79 1.66 5.70
Other Financing Activities, net
1.25 - 0.00 -0.34 -0.03 -0.09 8.80 2.55 0.84 0.00 0.00

Quarterly Cash Flow Statements for PAVmed

This table details how cash moves in and out of PAVmed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
5.90 -0.04 -25 0.42 1.52 1.30 -0.90 -1.57 4.92 -2.68 5.15
Net Cash From Operating Activities
-13 -12 -8.88 0.09 -1.58 -1.18 -0.90 -1.55 -2.62 -2.66 2.42
Net Cash From Continuing Operating Activities
-13 -12 -8.88 0.09 -1.58 -1.18 -0.90 -1.55 -2.62 -2.66 2.42
Net Income / (Loss) Continuing Operations
-19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60 -13
Consolidated Net Income / (Loss)
-19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60 -13
Depreciation Expense
0.59 0.31 0.24 0.07 0.04 0.02 0.02 0.02 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income
4.44 3.38 -69 -2.19 -20 11 4.91 1.01 -1.52 3.98 11
Changes in Operating Assets and Liabilities, net
0.38 -0.42 -0.52 1.08 -0.33 0.07 0.18 0.18 -0.06 -0.06 4.68
Net Cash From Investing Activities
-0.04 -0.00 -16 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01 -0.01
Net Cash From Continuing Investing Activities
-0.04 -0.00 -16 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01 -0.01
Purchase of Property, Plant & Equipment
-0.04 -0.00 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01 -0.01
Net Cash From Financing Activities
19 12 0.28 0.33 3.10 2.49 -0.00 - 7.56 - 2.74
Net Cash From Continuing Financing Activities
19 12 0.28 -0.02 3.10 2.49 -0.00 - 7.56 - 2.74
Issuance of Common Equity
0.85 0.20 0.28 0.33 3.21 2.49 - 4.86 0.00 - 2.74

Annual Balance Sheets for PAVmed

This table presents PAVmed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
1.21 0.87 1.64 8.50 7.24 20 87 54 33 31 39
Total Current Assets
0.78 0.74 1.62 8.46 6.55 19 83 44 24 2.16 2.26
Cash & Equivalents
0.77 0.59 1.54 8.22 6.22 17 77 40 20 1.19 1.24
Restricted Cash
- - - - - - - - - - 0.00
Accounts Receivable
- - - - - 0.00 0.20 0.02 0.06 0.02 0.02
Prepaid Expenses
0.01 0.16 0.09 0.24 0.33 1.69 5.18 4.05 4.52 0.96 1.00
Plant, Property, & Equipment, net
0.00 0.02 0.02 0.00 0.00 0.08 1.59 2.45 1.78 0.15 0.08
Total Noncurrent Assets
0.44 0.11 0.00 0.04 0.69 0.76 2.75 7.60 6.84 28 36
Long-Term Investments
- - - - - - - - 0.00 26 34
Other Noncurrent Operating Assets
0.44 0.11 - 0.04 0.69 0.76 0.73 4.16 5.41 2.71 2.36
Total Liabilities & Shareholders' Equity
1.21 0.87 1.64 8.50 7.24 20 87 54 33 31 39
Total Liabilities
0.58 1.19 4.49 11 12 20 7.56 43 57 38 17
Total Current Liabilities
0.58 1.19 2.54 11 12 16 7.56 41 54 35 15
Short-Term Debt
- - 0.00 7.90 8.14 10 0.00 34 44 29 11
Accounts Payable
0.17 0.95 0.86 1.74 2.35 2.97 3.30 2.70 1.79 0.66 0.68
Accrued Expenses
0.41 0.24 0.71 1.33 1.39 2.33 4.26 3.71 6.63 5.18 2.49
Other Current Liabilities
- 0.00 0.97 - - - 0.00 1.14 1.57 0.51 0.57
Total Noncurrent Liabilities
0.00 0.00 1.94 0.00 0.00 4.60 0.00 1.85 2.96 2.25 1.68
Other Noncurrent Operating Liabilities
- - - - 0.00 4.60 0.00 1.85 2.96 2.25 1.68
Commitments & Contingencies
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
0.63 -0.32 -2.85 -2.48 -4.64 -0.47 79 11 -24 -7.03 22
Total Preferred & Common Equity
0.63 -0.32 -2.85 -2.31 -3.82 1.90 62 -9.68 -54 -2.50 34
Preferred Stock
0.00 - 1.03 - 2.30 2.54 2.42 2.70 2.99 3.32 25
Total Common Equity
0.63 -0.32 -3.88 -2.31 -6.12 -0.64 59 -12 -57 -5.81 9.29
Common Stock
2.68 7.38 14 33 48 88 198 216 238 249 268
Retained Earnings
-2.05 -7.70 -18 -37 -54 -88 -139 -228 -294 -255 -259
Noncontrolling Interest
- - 0.00 -0.16 -0.81 -2.37 18 21 30 -4.54 -12

Quarterly Balance Sheets for PAVmed

This table presents PAVmed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
42 37 39 31 53 44 38 45 40 35
Total Current Assets
32 30 30 2.13 3.64 5.49 4.19 7.41 4.86 9.68
Cash & Equivalents
26 26 25 0.77 2.70 4.00 3.10 6.46 3.78 3.64
Restricted Cash
- - - - - - - - - 5.00
Accounts Receivable
0.04 0.07 0.22 0.02 0.01 0.00 0.00 0.02 0.02 0.03
Prepaid Expenses
6.02 3.56 3.80 1.34 0.93 1.48 1.09 0.93 1.06 1.02
Plant, Property, & Equipment, net
1.82 1.60 1.33 0.22 0.11 0.10 0.08 0.08 0.07 0.06
Total Noncurrent Assets
7.74 6.09 7.88 28 49 38 34 38 35 25
Long-Term Investments
- - - 26 47 36 32 36 33 24
Other Noncurrent Operating Assets
5.81 5.03 6.93 2.69 2.43 2.31 2.18 1.93 1.79 1.95
Total Liabilities & Shareholders' Equity
42 37 39 31 53 44 38 45 40 35
Total Liabilities
58 58 58 40 12 12 12 20 21 25
Total Current Liabilities
55 55 53 38 9.78 11 10 3.66 4.09 24
Short-Term Debt
45 46 44 32 6.60 6.80 6.90 0.00 0.00 14
Accounts Payable
2.17 1.49 1.23 0.47 0.37 0.39 0.34 0.98 1.06 1.04
Accrued Expenses
5.49 6.66 6.79 4.54 2.28 2.78 2.66 2.09 2.46 2.55
Other Current Liabilities
1.87 1.33 1.37 0.50 0.53 0.54 0.56 0.59 0.57 6.01
Total Noncurrent Liabilities
3.34 2.81 4.67 2.38 2.11 1.97 1.82 17 17 1.29
Other Noncurrent Operating Liabilities
3.34 2.81 4.67 2.38 2.11 1.97 1.82 1.87 1.72 1.29
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-16 -21 -19 -9.39 39 28 23 25 19 10
Total Preferred & Common Equity
-43 -69 -74 -4.87 45 38 33 40 35 27
Preferred Stock
2.92 3.07 3.15 3.23 26 25 24 3.76 3.85 3.95
Total Common Equity
-46 -72 -77 -8.10 19 13 8.45 36 31 24
Common Stock
232 238 244 248 256 264 265 295 296 300
Retained Earnings
-279 -310 -321 -256 -237 -251 -257 -259 -265 -276
Noncontrolling Interest
27 48 55 -4.52 -6.06 -9.37 -9.99 -15 -16 -17

Annual Metrics And Ratios for PAVmed

This table displays calculated financial ratios and metrics derived from PAVmed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 13,310,000.00 13,875,061.00 26,542,979.00 36,759,128.00 52,254,847.00 87,930,411.00 93,704,719.00 120,759,886.00 11,068,566.00 29,671,925.00
DEI Adjusted Shares Outstanding
0.00 34,240.00 35,694.00 68,283.00 94,564.00 134,427.00 226,204.00 241,059.00 310,659.00 368,952.00 989,064.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -165.04 -291.31 -274.60 -176.89 -257.11 -223.82 -370.30 -213.32 86.64 -3.82
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -24.60% 550.40% 22.15% -97.63%
EBITDA Growth
0.00% 0.00% -49.46% -43.85% -26.76% -90.48% -79.04% -79.55% 23.10% 47.10% 93.96%
EBIT Growth
0.00% 0.00% -55.63% -56.43% -11.97% -90.46% -79.67% -83.44% 22.02% 47.57% 93.88%
NOPAT Growth
0.00% 0.00% -42.18% -31.48% -35.33% -63.35% -132.94% -67.46% 24.47% 7.62% 65.69%
Net Income Growth
0.00% 0.00% -68.46% -90.91% 4.98% -107.83% -56.39% -83.94% 23.22% 135.86% -108.69%
EPS Growth
0.00% 0.00% -61.36% -14.08% 33.33% -168.52% 55.17% -83.94% 39.06% 135.86% -108.69%
Operating Cash Flow Growth
0.00% -256.50% -48.34% -32.98% -51.99% -64.06% -85.23% -74.88% 26.69% 35.52% 84.48%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% -72.10% -43.27% -15.98% -307.06% -39.57% 33.99% 10.65% 54.68%
Invested Capital Growth
0.00% 0.00% -169.59% -14.60% 2.76% -171.12% 129.31% 124.07% -88.78% -975.69% 52.51%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 150.00% -33.27% 61.85% -25.76% 144.83%
EBITDA Q/Q Growth
0.00% 0.00% -9.97% -102.83% -15.13% 19.01% -68.05% -3.97% 9.26% 31.00% -241.27%
EBIT Q/Q Growth
0.00% 0.00% -11.94% -88.87% -15.12% 18.94% -68.77% -4.49% 8.94% 31.14% -263.23%
NOPAT Q/Q Growth
0.00% 0.00% -2.26% -15.57% -9.80% -16.77% -27.52% -5.71% 10.67% 20.10% 24.41%
Net Income Q/Q Growth
0.00% 0.00% 21.33% -37.61% -16.59% 32.44% -117.80% -4.98% 8.29% 187.78% -272.66%
EPS Q/Q Growth
0.00% 0.00% 22.83% -17.39% -31.71% -35.51% -27.45% -4.98% 3.58% 187.78% -272.66%
Operating Cash Flow Q/Q Growth
0.00% -14.23% -6.17% -19.47% -8.71% -13.69% -32.90% -0.06% 8.68% 26.29% -46.19%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 38.44% -8.42% 13.35% -58.74% 5.07% 11.20% 20.53% 18.44%
Invested Capital Q/Q Growth
0.00% 0.00% 66.38% -25.92% -33.72% -190.81% 189.85% -33.43% -80.28% -31.61% -11.18%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.00% -858.62% -161.83% -61.60% -207.04%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,497.00% -24,996.02% -2,955.34% -1,280.00% -3,259.15%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,878.60% -24,161.01% -2,805.67% -1,485.38% -30,712.68%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,542.20% -25,647.75% -3,074.92% -1,320.00% -3,407.04%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,225.20% -27,384.08% -3,232.59% 949.15% -3,477.46%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 108.24% 132.10% 112.10% 122.33% 106.48% 106.77% 105.13% -71.91% 102.07%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,821.74% -1,789.21% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,727.02% -2,126.09% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,593.22% 3,000.81% 0.00% 0.00%
Return on Equity (ROE)
-280.26% -3,589.54% 601.07% 682.61% 485.45% 1,404.34% -142.19% -228.52% 1,211.60% -183.10% -32.34%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,203.89% -1,898.31% -1,629.56% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -98.75% -137.19% -173.13% -123.97% -6.96%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -105.15% -146.48% -182.01% 89.14% -7.11%
Return on Common Equity (ROCE)
-280.26% -3,589.54% 797.04% 794.29% 575.56% 1,857.71% -105.56% -118.55% 6,408.04% -369.34% -7.37%
Return on Equity Simple (ROE_SIMPLE)
-280.26% 1,771.05% 334.20% 785.12% 451.57% -1,892.83% -91.02% 1,066.40% 147.24% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.24 -3.96 -5.62 -7.39 -10 -16 -38 -64 -48 -44 -15
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,615.02% -16,912.71% -1,963.97% -1,485.38% -21,498.87%
Net Nonoperating Expense Percent (NNEP)
-69.46% -289.45% -4,415.69% 23,918.64% 907.19% -785.46% -42.90% -94.72% 336.89% -543.34% 114.86%
Return On Investment Capital (ROIC_SIMPLE)
-196.18% - - - - - - - -238.61% -201.60% -45.70%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 117.00% 958.62% 261.83% 161.60% 307.04%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,084.00% 10,984.08% 1,262.11% 818.83% 22,887.32%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,969.40% 6,720.95% 582.22% 198.06% 6,326.76%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,861.60% 23,302.39% 2,643.84% 1,423.77% 30,505.63%
Earnings before Interest and Taxes (EBIT)
-1.78 -5.65 -8.79 -14 -15 -29 -53 -97 -75 -40 -2.42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1.78 -5.65 -8.44 -12 -15 -29 -52 -94 -72 -38 -2.31
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 4.23 0.00 0.00 0.00 0.71
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 4.38 0.00 0.00 0.00 0.71
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 500.82 138.11 15.66 2.32 92.28
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.22 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 460.24% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 89.50 14.32 176.36 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 386.64 183.78 39.06 2.67 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 -0.68 -3.19 -1.75 -21.90 0.00 3.08 -1.84 -4.14 0.50
Long-Term Debt to Equity
0.00 0.00 -0.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.21 1.84 0.06 -0.02 -0.23 0.97 -1.07 -0.92 -1.41 -0.86 -1.46
Leverage Ratio
1.92 6.62 -0.79 -1.90 -2.21 -5.29 1.35 1.56 -6.66 -2.05 4.55
Compound Leverage Factor
1.92 6.62 -0.86 -2.51 -2.48 -6.47 1.44 1.67 -7.00 1.48 4.64
Debt to Total Capital
0.00% 0.00% -215.05% 145.63% 232.48% 104.78% 0.00% 75.48% 219.01% 131.87% 33.23%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 145.63% 232.48% 104.78% 0.00% 75.48% 219.01% 131.87% 33.23%
Long-Term Debt to Total Capital
0.00% 0.00% -215.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% -114.22% 0.00% 65.58% 25.66% 3.05% 6.04% 14.83% 15.03% 73.89%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% -2.98% -23.25% -23.96% 22.35% 46.24% 147.72% -20.56% -34.93%
Common Equity to Total Capital
100.00% 100.00% 429.27% -42.65% -174.81% -6.48% 74.60% -27.76% -281.56% -26.33% 27.81%
Debt to EBITDA
0.00 0.00 -0.23 -0.65 -0.53 -0.35 0.00 -0.36 -0.61 -0.76 -4.80
Net Debt to EBITDA
0.00 0.00 -0.05 0.03 -0.12 0.24 0.00 0.06 -0.34 -0.06 10.61
Long-Term Debt to EBITDA
0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 -0.35 -1.07 -0.81 -0.63 0.00 -0.53 -0.92 -0.65 -0.73
Net Debt to NOPAT
0.00 0.00 -0.07 0.04 -0.19 0.42 0.00 0.10 -0.51 -0.05 1.61
Long-Term Debt to NOPAT
0.00 0.00 -0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 19.20 -28.76 -10.18 -15.71 -7.14 16.68 -11.04 -20.56 -16.99 -9.68
Noncontrolling Interest Sharing Ratio
0.00% 0.00% -32.60% -16.36% -18.56% -32.28% 25.76% 48.12% -428.89% -101.72% 77.22%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.34 0.62 0.64 0.77 0.55 1.21 10.93 1.07 0.45 0.06 0.17
Quick Ratio
1.32 0.49 0.60 0.75 0.52 1.10 10.25 0.97 0.36 0.03 0.10
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 -4.09 -7.04 -10 -12 -48 -66 -44 -39 -18
Operating Cash Flow to CapEx
0.00% -20,441.69% -124,659.65% -33,026.07% -49,470.37% -39,843.64% -2,763.17% -4,609.42% 0.00% -61,007.27% -16,793.55%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -5.64 -1.59 -5.41 -1.79 -13.94 -9.89 -10.03 -8.56 -224.83
Operating Cash Flow to Interest Expense
0.00 0.00 -9.12 -1.99 -7.17 -3.35 -11.89 -10.57 -11.90 -7.33 -65.90
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -9.13 -2.00 -7.18 -3.35 -12.32 -10.80 -11.73 -7.34 -66.29
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.06 0.09 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.47 62.87 75.82 4.30
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.01 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.60 0.19 1.16 3.10 0.62
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.19 1.20 2.86 3.96 0.33
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 105.05 5.81 4.81 84.82
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.06 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 1,954.47 303.14 127.64 92.12 1,117.60
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 -1,954.47 -198.09 -110.77 -87.30 -1,032.78
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.13 -0.90 -2.44 -2.80 -2.72 -7.37 2.16 4.84 0.54 -4.76 -2.26
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 -0.19 0.11 0.91 -1.42 -0.02
Increase / (Decrease) in Invested Capital
0.00 0.00 -1.53 -0.36 0.08 -4.65 9.53 2.68 -4.30 -5.30 2.50
Enterprise Value (EV)
0.00 106 38 29 54 122 193 69 96 8.00 -5.00
Market Capitalization
0.00 106 37 30 51 128 250 52 38 6.95 6.55
Book Value per Share
$0.06 ($0.02) ($0.28) ($0.09) ($0.17) ($0.01) $0.67 ($0.13) ($0.47) ($0.53) $0.31
Tangible Book Value per Share
$0.06 ($0.02) ($0.28) ($0.09) ($0.17) ($0.01) $0.65 ($0.17) ($0.48) ($0.53) $0.31
Total Capital
0.63 -0.32 -0.90 5.43 3.50 9.89 79 45 20 22 33
Total Debt
0.00 0.00 1.94 7.90 8.14 10 0.00 34 44 29 11
Total Long-Term Debt
0.00 0.00 1.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-0.77 -0.59 0.41 -0.32 1.92 -6.90 -77 -6.09 25 2.28 -25
Capital Expenditures (CapEx)
0.00 0.02 0.01 0.03 0.03 0.06 1.47 1.54 -0.76 0.06 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.57 -1.03 -2.46 -2.83 -3.41 -3.61 -2.18 -3.37 -5.12 -5.37 -2.72
Debt-free Net Working Capital (DFNWC)
0.20 -0.45 -0.92 5.39 2.81 14 75 36 15 -4.18 -1.18
Net Working Capital (NWC)
0.20 -0.45 -0.92 -2.51 -5.33 3.29 75 2.73 -30 -33 -12
Net Nonoperating Expense (NNE)
0.53 1.70 3.90 11 7.26 20 18 39 31 -73 -13
Net Nonoperating Obligations (NNO)
-0.77 -0.59 0.41 -0.32 1.92 -6.90 -77 -6.09 25 2.28 -25
Total Depreciation and Amortization (D&A)
0.00 0.00 0.35 1.62 0.01 0.02 0.23 2.46 2.93 1.20 0.11
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -435.80% -893.37% -208.73% -179.20% -3,828.17%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15,015.80% 9,648.81% 592.21% -139.63% -1,661.97%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15,015.80% 723.08% -1,210.40% -1,111.25% -17,295.77%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) ($9.16) $99.00 ($5.63)
Adjusted Weighted Average Basic Shares Outstanding
0.00 1.00M 1.33M 2.15M 2.33M 6.36M 6.77M 6.87M 7.23M 322.41K 670.47K
Adjusted Diluted Earnings per Share
$0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) ($9.16) $15.00 ($5.63)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 1.00M 1.33M 2.15M 2.33M 6.36M 6.77M 7.60M 7.23M 2.18M 670.47K
Adjusted Basic & Diluted Earnings per Share
$0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 1.00M 1.04M 1.72M 2.33M 3.66M 5.98M 7.60M 9.17M 559.57K 6.38M
Normalized Net Operating Profit after Tax (NOPAT)
-1.24 -3.96 -5.62 -7.39 -10 -16 -38 -64 -48 -31 -15
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,615.02% -16,912.71% -1,963.97% -1,039.76% -21,498.87%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,225.20% -27,384.08% -3,232.59% 949.15% -3,477.46%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -12.14 -3.12 -8.26 -4.48 -15.44 -14.40 -17.25 -8.63 -30.62
NOPAT to Interest Expense
0.00 0.00 -7.76 -1.67 -5.37 -2.50 -11.15 -9.50 -11.02 -9.71 -193.22
EBIT Less CapEx to Interest Expense
0.00 0.00 -12.14 -3.12 -8.28 -4.49 -15.87 -14.63 -17.08 -8.64 -31.01
NOPAT Less CapEx to Interest Expense
0.00 0.00 -7.77 -1.68 -5.38 -2.50 -11.58 -9.72 -10.84 -9.73 -193.61
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-4.06% 0.00% -4.08% 0.00% 0.00% 0.00% -2.34% 0.00% 0.00% 0.00% -4.41%

Quarterly Metrics And Ratios for PAVmed

This table displays calculated financial ratios and metrics derived from PAVmed's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
9,172,331.00 9,431,721.00 10,406,433.00 11,068,566.00 16,787,173.00 17,618,034.00 21,932,914.00 29,671,925.00 6,383,089.00 7,272,739.00 7,995,918.00
DEI Adjusted Shares Outstanding
305,744.00 314,391.00 346,881.00 368,952.00 559,572.00 587,268.00 731,097.00 989,064.00 6,383,089.00 7,272,739.00 7,995,918.00
DEI Earnings Per Adjusted Shares Outstanding
-74.53 -34.70 185.41 3.65 31.62 -22.66 -8.66 -1.85 -1.09 -0.75 -1.47
Growth Metrics
- - - - - - - - - - -
Revenue Growth
126.46% 489.76% 25.92% -99.05% -99.21% -99.39% -99.50% 420.00% 175.00% 450.00% 720.00%
EBITDA Growth
25.30% 14.64% 48.00% 107.59% 219.90% 11.75% 40.05% -325.27% -87.38% 46.47% -117.29%
EBIT Growth
25.10% 16.59% 48.72% 106.85% 215.30% 13.49% 41.23% -340.40% -87.46% 46.41% -116.81%
NOPAT Growth
31.20% 16.99% -6.52% 54.75% 44.57% 65.54% 70.71% 8.25% -3.28% -48.93% -38.87%
Net Income Growth
16.67% 16.64% 379.13% 106.56% 200.60% 17.37% -109.90% -341.42% -105.71% 46.46% -116.85%
EPS Growth
5.76% 43.33% 160.50% 106.56% 200.60% 17.37% -120.14% -341.42% -143.76% 96.06% 0.00%
Operating Cash Flow Growth
19.88% 8.30% 19.89% 100.79% 87.94% 89.89% 89.91% -1,750.00% -65.72% -126.06% 369.53%
Free Cash Flow Firm Growth
82.94% 58.82% 17.97% 101.52% -22.68% 62.65% 4.57% -6,758.44% -15.58% -130.77% 121.72%
Invested Capital Growth
-109.80% -102.82% -231.19% -975.69% -216.81% -1,164.54% 43.79% 52.51% -42.07% -61.02% -285.03%
Revenue Q/Q Growth
-3.72% -3.07% 1.74% -99.00% -20.00% -25.00% -16.67% 940.00% -57.69% 50.00% 24.24%
EBITDA Q/Q Growth
2.48% 10.68% 28.34% 112.16% 1,440.74% -165.74% 51.32% 54.31% 186.30% -378.87% -97.63%
EBIT Q/Q Growth
3.20% 12.03% 28.20% 111.20% 1,529.76% -166.01% 51.22% 54.18% 185.01% -382.07% -97.35%
NOPAT Q/Q Growth
14.32% 2.51% -20.87% 55.18% -4.95% 39.40% -2.74% -40.40% -18.14% 12.61% 4.20%
Net Income Q/Q Growth
-6.35% 19.44% 507.07% -98.12% 1,530.74% -166.18% 51.23% 54.13% 61.41% -520.11% -97.56%
EPS Q/Q Growth
-19.09% 54.58% 221.01% -98.12% 1,530.74% -166.18% 60.81% 54.13% -61.90% 80.32% 0.00%
Operating Cash Flow Q/Q Growth
-10.40% 11.08% 23.79% 101.06% -1,781.91% 25.49% 23.94% -73.10% -68.92% -1.64% 190.69%
Free Cash Flow Firm Q/Q Growth
52.16% -29.46% -17.34% 102.09% -3,960.55% 60.59% -199.84% -45.95% 32.99% 21.30% 128.22%
Invested Capital Q/Q Growth
-205.16% 75.31% -2,462.41% -31.61% 61.96% 1.44% -13.91% -11.18% -13.82% -11.71% -172.38%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-72.67% -70.17% -38.65% -390.00% -350.00% -583.33% -1,000.00% -65.38% -340.91% -269.70% -285.37%
EBITDA Margin
-1,545.84% -1,424.41% -1,003.31% 12,150.00% 234,000.00% -205,100.00% -119,820.00% -5,263.46% 10,736.36% -19,960.61% -31,751.22%
Operating Margin
-1,389.70% -1,397.75% -1,162.45% -51,890.00% -68,075.00% -78,583.33% -96,880.00% -13,078.85% -36,522.73% -21,278.79% -16,407.32%
EBIT Margin
-1,603.86% -1,455.57% -1,027.21% 11,460.00% 233,462.50% -205,466.67% -120,260.00% -5,298.08% 10,645.45% -20,018.18% -31,797.56%
Profit (Net Income) Margin
-1,832.87% -1,523.39% 6,095.48% 11,420.00% 232,787.50% -205,400.00% -120,220.00% -5,301.92% -4,836.36% -19,993.94% -31,792.68%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
114.28% 104.66% -593.40% 99.65% 99.71% 99.97% 99.97% 100.07% -45.43% 99.88% 99.98%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-1,117.05% -1,543.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-1,232.69% -1,586.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
1,895.40% 1,982.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
778.35% 439.60% -78.35% -183.10% 644.12% 1,066.79% 17.44% -32.34% -67.22% -64.78% -130.63%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-94.35% -119.73% -114.20% 1,076.30% 10,330.96% -5,031.47% -101.65% -10.83% 18.42% -53.31% -128.45%
Return on Assets (ROA)
-107.82% -125.31% 677.67% 1,072.54% 10,301.09% -5,029.84% -101.62% -10.84% -8.37% -53.25% -128.43%
Return on Common Equity (ROCE)
7,701.04% 2,516.06% -168.65% -369.34% -1,681.26% -5,354.92% 0.37% -7.37% -55.56% -56.39% -116.27%
Return on Equity Simple (ROE_SIMPLE)
109.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.83 -9.58 -12 -5.19 -5.45 -3.30 -3.39 -4.76 -5.62 -4.92 -4.71
NOPAT Margin
-972.79% -978.43% -1,162.45% -51,890.00% -68,075.00% -55,008.33% -67,816.00% -9,155.19% -25,565.91% -14,895.15% -11,485.12%
Net Nonoperating Expense Percent (NNEP)
115.64% 43.86% -593.60% -47.18% 211.72% -122.76% -23.77% 17.99% 12.97% -6.08% -36.39%
Return On Investment Capital (ROIC_SIMPLE)
-39.36% -37.77% -51.09% -23.51% -11.96% -9.44% -11.52% -14.25% -14.10% -14.29% -19.36%
Cost of Revenue to Revenue
172.67% 170.17% 138.65% 490.00% 450.00% 683.33% 1,100.00% 165.38% 440.91% 369.70% 385.37%
SG&A Expenses to Revenue
661.19% 715.93% 667.57% 41,880.00% 54,800.00% 61,166.67% 70,100.00% 9,021.15% 28,890.91% 14,093.94% 10,931.71%
R&D to Revenue
192.18% 167.62% 154.82% 8,080.00% 9,837.50% 13,166.67% 21,760.00% 3,513.46% 6,309.09% 6,263.64% 4,687.80%
Operating Expenses to Revenue
1,317.03% 1,327.58% 1,123.80% 51,500.00% 67,725.00% 78,000.00% 95,880.00% 13,013.46% 36,181.82% 21,009.09% 16,121.95%
Earnings before Interest and Taxes (EBIT)
-16 -14 -10 1.15 19 -12 -6.01 -2.76 2.34 -6.61 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-16 -14 -9.99 1.22 19 -12 -5.99 -2.74 2.36 -6.59 -13
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.65 0.82 1.12 0.71 1.81 1.38 1.26
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.65 0.82 1.12 0.71 1.81 1.38 1.26
Price to Revenue (P/Rev)
6.51 2.01 3.17 2.32 6.08 10.37 325.97 92.28 762.22 385.71 199.36
Price to Earnings (P/E)
0.00 0.00 0.87 0.22 0.17 0.15 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 114.96% 460.24% 598.24% 662.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
30.14 22.11 4.29 2.67 0.00 0.00 0.00 0.00 311.20 81.53 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-2.21 -2.36 -3.41 -4.14 0.16 0.22 0.27 0.50 0.60 0.78 1.40
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60 0.78 0.00
Financial Leverage
-1.54 -1.25 -0.97 -0.86 -1.12 -1.15 -1.34 -1.46 -1.07 -1.09 -1.27
Leverage Ratio
-10.49 -4.78 -2.88 -2.05 4.42 6.52 4.18 4.55 1.49 1.66 2.04
Compound Leverage Factor
-11.99 -5.00 17.08 -2.05 4.41 6.52 4.18 4.55 -0.68 1.66 2.04
Debt to Total Capital
182.42% 173.52% 141.42% 131.87% 13.89% 17.79% 21.11% 33.23% 37.35% 43.89% 58.38%
Short-Term Debt to Total Capital
182.42% 173.52% 141.42% 131.87% 13.89% 17.79% 21.11% 33.23% 0.00% 0.00% 58.38%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 37.35% 43.89% 0.00%
Preferred Equity to Total Capital
12.30% 12.43% 14.26% 15.03% 55.28% 64.29% 73.63% 73.89% 9.42% 11.19% 16.22%
Noncontrolling Interests to Total Capital
193.09% 218.09% -19.94% -20.56% -8.55% -15.99% -20.60% -34.93% -36.44% -45.75% -71.26%
Common Equity to Total Capital
-287.81% -304.03% -35.75% -26.33% 39.38% 33.91% 25.86% 27.81% 89.67% 90.67% 96.65%
Debt to EBITDA
-0.68 -0.68 -0.58 -0.76 -1.65 -2.88 4.21 -4.80 -0.80 -1.17 -0.71
Net Debt to EBITDA
-0.30 -0.29 -0.10 -0.06 10.68 14.04 -16.98 10.61 1.48 1.71 0.90
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.80 -1.17 0.00
Debt to NOPAT
-1.04 -1.05 -0.58 -0.65 -0.18 -0.25 -0.34 -0.73 -0.87 -0.81 -0.71
Net Debt to NOPAT
-0.46 -0.44 -0.10 -0.05 1.19 1.23 1.38 1.61 1.61 1.19 0.90
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.87 -0.81 0.00
Altman Z-Score
-13.61 -13.11 -13.92 -12.61 -4.61 -8.52 -9.70 -9.71 -5.81 -8.49 -11.98
Noncontrolling Interest Sharing Ratio
-889.41% -472.36% -115.25% -101.72% 361.02% 601.96% 97.85% 77.22% 17.35% 12.95% 10.99%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.54 0.57 0.06 0.06 0.37 0.52 0.40 0.17 2.02 1.19 0.41
Quick Ratio
0.47 0.48 0.02 0.03 0.28 0.38 0.30 0.10 1.77 0.93 0.15
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.43 -4.44 -5.21 0.11 -4.21 -1.66 -4.97 -7.26 -4.86 -3.83 1.08
Operating Cash Flow to CapEx
-31,211.90% -388,533.33% -148,050.00% 2,350.00% -26,350.00% -14,725.00% -29,866.67% -11,078.57% -11,909.09% -20,484.62% 30,187.50%
Free Cash Flow to Firm to Interest Expense
-1.44 -5.74 -3.68 18.17 -67.87 -414.63 -621.60 -1,451.54 -1.42 -1,913.70 216.02
Operating Cash Flow to Interest Expense
-5.50 -15.06 -6.28 15.67 -25.50 -294.50 -112.00 -310.20 -0.77 -1,331.50 483.00
Operating Cash Flow Less CapEx to Interest Expense
-5.51 -15.06 -6.28 15.00 -25.60 -296.50 -112.38 -313.00 -0.77 -1,338.00 481.40
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.06 0.08 0.11 0.09 0.04 0.02 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
64.17 29.45 155.15 75.82 52.45 9.19 3.05 4.30 5.67 11.79 8.71
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.57 2.28 3.96 3.10 2.33 1.43 0.20 0.62 0.88 1.29 2.07
Accounts Payable Turnover
4.97 5.68 4.87 3.96 3.38 1.86 0.45 0.33 0.41 0.50 0.67
Days Sales Outstanding (DSO)
5.69 12.39 2.35 4.81 6.96 39.72 119.57 84.82 64.41 30.96 41.93
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
73.42 64.26 74.98 92.12 108.03 196.06 813.69 1,117.60 884.37 731.52 543.56
Cash Conversion Cycle (CCC)
-67.73 -51.87 -72.63 -87.30 -101.07 -156.34 -694.12 -1,032.78 -819.96 -700.56 -501.63
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.57 -0.14 -3.61 -4.76 -1.81 -1.78 -2.03 -2.26 -2.57 -2.87 -7.82
Invested Capital Turnover
1.15 1.58 -9.39 -1.42 -1.67 -1.06 -0.01 -0.02 -0.04 -0.05 -0.03
Increase / (Decrease) in Invested Capital
-6.40 -5.14 -6.37 -5.30 -1.24 -1.64 1.58 2.50 -0.76 -1.09 -5.79
Enterprise Value (EV)
91 85 17 8.00 -8.41 -4.17 -1.03 -5.00 26 9.13 -1.82
Market Capitalization
20 7.69 13 6.95 12 11 9.45 6.55 65 43 30
Book Value per Share
($7.83) ($8.17) ($0.78) ($0.53) $1.11 $0.74 $0.39 $0.31 $5.60 $4.29 $2.94
Tangible Book Value per Share
($7.95) ($8.27) ($0.78) ($0.53) $1.11 $0.74 $0.39 $0.31 $5.60 $4.29 $2.94
Total Capital
25 25 23 22 48 38 33 33 40 34 24
Total Debt
46 44 32 29 6.60 6.80 6.90 11 15 15 14
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 0.00
Net Debt
20 19 5.77 2.28 -43 -33 -28 -25 -28 -22 -18
Capital Expenditures (CapEx)
0.04 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.44 -4.68 -4.14 -5.37 -2.24 -2.22 -2.47 -2.72 -2.71 -3.01 -8.55
Debt-free Net Working Capital (DFNWC)
20 21 -3.38 -4.18 0.46 1.78 0.63 -1.18 3.75 0.77 0.09
Net Working Capital (NWC)
-25 -23 -35 -33 -6.14 -5.02 -6.27 -12 3.75 0.77 -14
Net Nonoperating Expense (NNE)
8.69 5.34 -72 -6.33 -24 9.02 2.62 -2.00 -4.56 1.68 8.33
Net Nonoperating Obligations (NNO)
20 19 5.77 2.28 -43 -33 -28 -25 -28 -22 -18
Total Depreciation and Amortization (D&A)
0.59 0.31 0.24 0.07 0.04 0.02 0.02 0.02 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue
-180.27% -122.28% -102.68% -179.20% -112.54% -217.84% -8,520.69% -3,828.17% -3,188.24% -2,691.07% -5,775.00%
Debt-free Net Working Capital to Revenue
666.41% 543.67% -83.71% -139.63% 22.93% 174.71% 2,179.31% -1,661.97% 4,411.76% 687.50% 59.46%
Net Working Capital to Revenue
-843.53% -605.46% -878.21% -1,111.25% -308.23% -491.96% -21,613.79% -17,295.77% 4,411.76% 687.50% -9,535.14%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.62) $0.00 $6.43 $125.10 $38.40 ($22.20) ($0.29) ($81.90) ($4.42) ($0.87) ($1.77)
Adjusted Weighted Average Basic Shares Outstanding
8.69M 9.15M 10.01M 10.75K 462.54K 602.82K 21.55M 22.35K 1.58M 6.27M 6.64M
Adjusted Diluted Earnings per Share
($2.62) ($1.19) $1.44 $125.10 $10.20 ($22.20) ($0.29) ($81.90) ($4.42) ($0.87) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
8.69M 9.15M 44.48M 72.45K 1.75M 602.82K 21.55M 22.35K 1.58M 6.27M 8.00M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $125.10 $0.00 $0.00 $0.00 ($81.90) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
9.43M 10.41M 11.07M 559.57K 587.27K 731.10K 29.67M 212.77K 7.27M 8.00M 8.00M
Normalized Net Operating Profit after Tax (NOPAT)
-9.83 -9.58 -8.10 -3.63 -3.81 -3.30 -3.39 -4.76 -5.62 -4.92 -4.71
Normalized NOPAT Margin
-972.79% -978.43% -813.71% -36,323.00% -47,652.50% -55,008.33% -67,816.00% -9,155.19% -25,565.91% -14,895.15% -11,485.12%
Pre Tax Income Margin
-1,832.87% -1,523.39% 6,095.48% 11,420.00% 232,787.50% -205,400.00% -120,220.00% -5,301.92% -4,836.36% -19,993.94% -31,792.68%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-6.79 -18.41 -7.23 191.00 301.24 -3,082.00 -751.63 -551.00 0.68 -3,303.00 -2,607.40
NOPAT to Interest Expense
-4.12 -12.38 -8.18 -864.83 -87.84 -825.13 -423.85 -952.14 -1.64 -2,457.70 -941.78
EBIT Less CapEx to Interest Expense
-6.81 -18.41 -7.23 190.33 301.15 -3,084.00 -752.00 -553.80 0.68 -3,309.50 -2,609.00
NOPAT Less CapEx to Interest Expense
-4.14 -12.38 -8.19 -865.50 -87.94 -827.13 -424.23 -954.94 -1.65 -2,464.20 -943.38
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.17% 0.16% 0.00% -4.41% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

PAVmed’s third-quarter 2026 results show modest sequential progress in revenue and operating costs, but the company remains far from operating profitability. Revenue rose to $41,000 from $33,000 in Q2 and $22,000 in Q1, while operating expenses declined to $6.61 million from $6.93 million and $7.96 million, respectively. Still, revenue remains very small relative to expenses, and the company reported a $13.04 million consolidated net loss for Q3.

Liquidity and cash-flow figures require careful interpretation. PAVmed reported $2.42 million in cash from operations in Q3, but that result included $10.75 million in noncash adjustments and a $4.68 million contribution from changes in operating assets and liabilities. Operating cash flow for the first three quarters of 2026 was still negative by about $2.87 million. The balance sheet also lists $5 million of restricted cash, which may not be available for general use.

  • Revenue increased in each of the first three quarters of 2026, reaching $41,000 in Q3, up from $22,000 in Q1. The rise is encouraging, although the overall revenue level remains very low.
  • Quarterly operating expenses declined from $7.96 million in Q1 to $6.61 million in Q3, and the operating loss narrowed from $8.04 million to $6.73 million over that period.
  • Q3 operating cash flow turned positive at $2.42 million, compared with cash used in operations of $2.66 million in Q2. However, the positive result depended heavily on noncash adjustments and working-capital changes, while year-to-date operating cash flow remained negative.
  • The company continues to generate substantial losses: Q3 consolidated net loss was $13.04 million, compared with $6.60 million in Q2. A $6.31 million net other expense contributed to the larger loss.
  • Current liabilities reached $23.80 million versus current assets of $9.68 million at Q3-end. The resulting working-capital deficit is significant, and $5 million of current assets is reported as restricted cash.
  • Short-term debt rose from zero in Q2 to $14.20 million in Q3, while long-term debt fell from $15.10 million to zero. Total reported debt declined slightly, but the shift to short-term classification increases near-term repayment and refinancing pressure.
  • PAVmed raised $2.74 million through common-equity issuance in Q3. Equity financing helped support cash, but continued reliance on share issuance can dilute existing shareholders.
  • The longer-term revenue trend remains weak: quarterly revenue was about $1 million in Q1–Q3 2024, fell to just $5,000–$8,000 in the comparable 2025 quarters, and was only $22,000–$41,000 in the first three quarters of 2026.
11/21/26 07:33 PM ETAI Generated. May Contain Errors.

PAVmed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PAVmed's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

PAVmed's net income appears to be on a downward trend, with a most recent value of -$2.47 million in 2025, falling from -$1.78 million in 2015. The previous period was $28.43 million in 2024. View PAVmed's forecast to see where analysts expect PAVmed to go next.

PAVmed's total operating income in 2025 was -$21.81 million, based on the following breakdown:
  • Total Gross Profit: -$147 thousand
  • Total Operating Expenses: $21.66 million

Over the last 10 years, PAVmed's total revenue changed from $0.00 in 2015 to $71 thousand in 2025, a change of 7,100,000.0%.

In the past 12 quarters, PAVmed's cash and equivalents has ranged from $765 thousand in Q3 2024 to $26.41 million in Q3 2023, and is currently $3.64 million as of their latest financial filing in Q3 2026.

PAVmed had total debt of $11.10 million at the end of 2025, a 61.9% decrease from 2024, and none in 2015.

Over the last 10 years, PAVmed's book value per share changed from 0.06 in 2015 to 0.31 in 2025, a change of 457.1%.



Financial statements for NASDAQ:PAVM last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners